ArticleNeuromolecular medicine2004
Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro.
Article in Neuromolecular medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- The role of macrophage plasticity in neurodegenerative diseases.Biomarker research · 2024Review
- Molecular hallmarks of ageing in amyotrophic lateral sclerosis.Cellular and molecular life sciences : CMLS · 2024Review
- Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer's Disease.Stem cells translational medicine · 2016Article
- Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Current medicinal chemistry · 2014Article
- A novel approach to study motor neurons from zebrafish embryos and larvae in culture.Journal of neuroscience methods · 2012Article
- Vascular endothelial growth factor prevents G93A-SOD1-induced motor neuron degeneration.Developmental neurobiology · 2009Article
- Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression.Gene therapy · 2009Article
- Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases · 2009Review
- IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury.Experimental neurology · 2009Article
- Insulin-like growth factors in the peripheral nervous system.Endocrinology · 2008Review
- Article
- Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.Brain research · 2007Article
- SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy.Experimental neurology · 2007Article
- Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide.Journal of neuro-oncology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Recent work has demonstrated that adeno-associated viral (AAV) vector-mediated delivery of the insulin-like growth factor (IGF-I) gene through retrograde axonal transport can prolong survival and delay disease onset in the superoxide dismutase mutant mouse model of motor neuron (MN) disease. The present experiment examines IGF-I gene transfer in vitro. Adenoviral and AAV vectors for IGF-I infect neurons triggering expression and secretion of biologically active IGF-I. AAV-mediated IGF-I expression in SH-SY5Y neurons protects both cells expressing the transgene, and bystanders without transgene expression from glutamate-induced apoptosis. Similarly, AAV-mediated IGF-I delivery in primary E15 MN culture provides a titer-dependent neuroprotection from glutamate-induced DNA fragmentation. Both infected and noninfected neurons are equally protected. These observations argue that vector-mediated IGF-I gene transfer induces secretion of active IGF-I that acts through direct effects on spinal cord MNs. This mechanism may explain the therapeutic effects observed in vivo despite relatively low affinity AAV spinal cord uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.